Epigenetic Control of CDK5 Promoter Regulates Diabetes-Associated Development of Alzheimer's Disease

被引:8
|
作者
Cai, Hong-Bin [1 ]
Fan, Zhen-Zhen [1 ]
Tian, Ting [1 ]
Zhao, Chon-Chon [1 ]
Ge, Zhao-Ming [1 ]
机构
[1] Lanzhou Univ, Dept Neurol, Hosp 2, 82 Cuiyingmen, Lanzhou 730000, Gansu, Peoples R China
关键词
Alzheimer's disease; cyclin-dependent kinase-5; diabetes; methylation; promoter acetylation; tau; AMYLOID-BETA; P35; PATHOGENESIS; DYSFUNCTION; AUTOPHAGY; ACTIVATOR;
D O I
10.3233/JAD-190227
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cyclin-dependent kinase-5 (CDK5) is activated by p35 and then binds to both p35 and its truncated form p25 to promote hyperphosphorylation of tau protein, thereby facilitating the pathological progression of Alzheimer's disease (AD). However, it is unknown whether a patient's diabetic status promotes the later onset of AD in a CDK5-dependent manner. Here, we induced pro-diabetic insulin resistance and glucose intolerance in rats using a combined high fat and high glucose diet. Compared to normal diet-fed rats, these pro-diabetic rats exhibited poorer behavioral performance in the Morris water maze test and the novel object recognition test. Increased phosphorylation of tau protein was detected in the hippocampal CAl region of the rat brain, suggesting neurodegeneration. Moreover, CDK5 transcriptional activity was significantly increased in the HFGD-rat brain, likely resulting from an increase in acetylation and a decrease in methylation of the CDK5 promoter. Together, these data suggest that epigenetic control of the CDK5 promoter by acetylation and methylation may regulate the diabetes-associated development of AD.
引用
收藏
页码:743 / 750
页数:8
相关论文
共 50 条
  • [21] Alzheimer's disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk
    Sjolander, Annica
    Andersson, Malin E.
    Zetterberg, Henrik
    Minthon, Lennart
    Bogdanovic, Nenad
    Blennow, Kaj
    MOLECULAR MEDICINE REPORTS, 2009, 2 (06) : 989 - 992
  • [22] Alzheimer's disease and diabetes-associated cognitive dysfunction: the microglia link?
    Liu, Yaqiong
    Li, Tao
    Xiong, Juliang
    METABOLIC BRAIN DISEASE, 2025, 40 (01)
  • [23] Association between plasma biomarkers, CDK5 polymorphism and the risk of Alzheimer's disease
    Czapski, Grzegorz A.
    Maruszak, Aleksandra
    Styczynska, Maria
    Zekanowski, Cezary
    Safranow, Krzysztof
    Strosznajder, Joanna B.
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2012, 72 (04) : 397 - 411
  • [24] CDK5 Targeting as a Therapy for Recovering Neurovascular Unit Integrity in Alzheimer's Disease
    Andres Posada-Duque, Rafael
    Patricia Cardona-Gomez, Gloria
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 82 : S141 - S161
  • [25] Crosstalk between Cdk5 and GSK3β: implications for Alzheimer's disease
    Engmann, Olivia
    Giese, Karl Peter
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2009, 2
  • [26] Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease
    L Crews
    C Patrick
    A Adame
    E Rockenstein
    E Masliah
    Cell Death & Disease, 2011, 2 : e120 - e120
  • [27] Addressing the complex etiology of Alzheimer's disease: the role of p25/Cdk5
    Mungenast, Alison E.
    Tsai, Li-Huei
    FUTURE NEUROLOGY, 2011, 6 (04) : 481 - 496
  • [28] Multifaceted Regulation of ALDH1A1 by Cdk5 in Alzheimer’s Disease Pathogenesis
    Kumar Nikhil
    Keith Viccaro
    Kavita Shah
    Molecular Neurobiology, 2019, 56 : 1366 - 1390
  • [29] Multifaceted Regulation of ALDH1A1 by Cdk5 in Alzheimer's Disease Pathogenesis
    Nikhil, Kumar
    Viccaro, Keith
    Shah, Kavita
    MOLECULAR NEUROBIOLOGY, 2019, 56 (02) : 1366 - 1390
  • [30] Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease
    Crews, L.
    Patrick, C.
    Adame, A.
    Rockenstein, E.
    Masliah, E.
    CELL DEATH & DISEASE, 2011, 2 : e120 - e120